Product
Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-derived CD22 CAR Therapy
1 clinical trial
3 indications
Indication
B-cell Acute Lymphoblastic LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
RelapseClinical trial
Safety, Tolerability and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allogeneic Haematopoietic Stem Cell Transplantation and Sequential Donor-derived CD22 CAR Therapy in Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia: a Clinical TrialStatus: Not yet recruiting, Estimated PCD: 2026-06-15